Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Repare Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Repare Therapeutics Inc.

RPTX

Repare Therapeutics Inc.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage biotech specializing in precision oncology through synthetic lethality. Using its proprietary SNIPRx platform, it develops targeted small-molecule therapeutics for genetically-defined cancers, focusing on DNA repair and genomic instability. Its portfolio includes candidates like RP-3467 and RP-1664, targeting DNA polymerase theta and PLK4, respectively. The company collaborates with industry partners, relies on third-party manufacturing, and aims to advance cancer treatments with a competitive edge in targeted therapy development.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Repare Therapeutics Inc.

1
1
Repare Therapeutics Inc. Repare Therapeutics Reports $11.6M Revenue in Q3 2025, Announces Acquisition by XenoTherapeutics

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Repare Therapeutics Inc. Repare Therapeutics Reports Significant Revenue Decline and Organizational Changes in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Repare Therapeutics Inc. Repare Therapeutics Reports $30M Net Loss and Zero Revenue in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Repare Therapeutics Inc. Repare Therapeutics Reports $84.7 Million Net Loss for 2024, Revenue Increases to $53.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Repare Therapeutics Inc. Repare Therapeutics Reports Q3 Financial Results, Net Loss Improves Amid Strategic Reprioritization and Reduced Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments